THERAPY DOSSIER · th-72026978471d

3,5,4'-tri-O-acetylresveratrol, a prodrug of resveratrol

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23219988 ↗2012Reported benefit

3,5,4'-Tri-O-acetylresveratrol attenuates seawater aspiration-induced lung injury by inhibiting activation of nuclear factor-kappa B and hypoxia-inducible factor-1alpha.

RatOtherSprague-DawleyMalePretreatment before seawater aspiration

Model: Seawater aspiration (drowning) induced acute lung injury

Pretreatment with different doses of 3,5,4'-tri-O-acetylresveratrol improved seawater-induced lung histopathological changes, alleviated lung oedema, reduced TNF-alpha and IL-1beta, inhibited malondialdehyde and enhanced total superoxide dismutase activity. The protection was associated with inhibi…

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…